Monday, September 24, 2001
Amid the sucking sound of the WTC market meltdown, Actelion
(SWX:ATLN) was one of the few companies rewarded for key milestones last week
(see Cover Story). The stock closed the week up CHF3 to CHF41 after the
FDA issued an approvable letter for Tracleer bosentan to treat pulmonary arterial
hypertension (PAH). But partner Genentech (DNA) fell $4.68 (11%) to $39.88
on the week.
Amgen (AMGN) also got no reward for FDA approval of
its Aranesp darepoetin alfa to treat anemia associated with chronic renal failure
and its filing of an sBLA for Aranesp to treat anemia associated with chemotherapy.
The stock closed the week down $8.11 (13%) at $56.02 after slipping $1.47 to
$59.38 on 20.1 million shares on Tuesday.